Loop Biz – Lifestyle
Author:
Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
April 30, 2026
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
March 31, 2026
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
March 12, 2026